BeOne Medicines (BEIGF) EBT Margin (2015 - 2026)

BeOne Medicines (BEIGF) has reported EBT Margin for 12 consecutive years, with 18.33% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT Margin rose 1076.0% year-over-year to 18.33% in Q2 2026; TTM through Jun 2026 was 14.16%, a 1555.0% increase from a year earlier, with the FY2025 full-year figure at 7.8%, up 2179.0% from the prior year.
• EBT Margin was 18.33% for Q2 2026 at BeOne Medicines, up from 17.13% in the prior quarter.
• Over five years, EBT Margin peaked at 29.35% in Q3 2023 and troughed at 163.24% in Q2 2022.
• A 5-year average of 39.72% and a median of 10.61% in 2024 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin tumbled 14759 bps in 2022 and jumped 17156 bps in 2023, its largest moves.
• Over 5 years, EBT Margin stood at 113.38% in 2022, then surged by 51 bps to 55.29% in 2023, then surged by 86 bps to 7.57% in 2024, then soared by 232 bps to 9.96% in 2025, then jumped by 84 bps to 18.33% in 2026.
• The last three EBT Margin figures came in at 18.33% (Q2 2026), 17.13% (Q1 2026), and 9.96% (Q4 2025), per Business Quant data.